Corvus Pharmaceuticals (CRVS)

• Market cap: $431M
• 1 day: 0.87%
• 5 days: -2.36%
• 1 month: 8.83%
• 3 months: 46.95%
• 6 months: 22.67%
• Year to date: 6.63%
• 1 year: 5.27%
• 5 years: 28.67%
• 10 years: -59.37%
• Sector: Healthcare
• Industry: Biotechnology

About: Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Employees: 31

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

256% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 9

45% more capital invested

Capital invested by funds: $115M [Q1] → $167M (+$51.9M) [Q2]

18% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 28

8.07% more ownership

Funds ownership: 53.23% [Q1] → 61.29% (+8.07%) [Q2]

6% more funds holding

Funds holding: 87 [Q1] → 92 (+5) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

30% less call options, than puts

Call options by funds: $702K | Put options by funds: $1.01M